Decapeptide-12

Decapeptide-12, a small oligopeptide, is a tyrosinase inhibitor that interacts with C-terminal residue of tyrosinase (Kd: 61.1 μM). Decapeptide-12 is a competitive inhibitor of mushroom tyrosinase (IC50: 40 µM). Decapeptide-12 also increases transcription of SIRT. Decapeptide-12 reduces melanin content in melanocytes. Decapeptide-12 is used for the research of melanogenesis, senescence, inflammation [1][2][3].

Signaling Pathways >> Epigenetics >> Sirtuin

Research Areas >> Endocrinology

Signaling Pathways >> Cell Cycle/DNA Damage >> Sirtuin

Research Areas >> Inflammation/Immunology

Signaling Pathways >> Metabolic Enzyme/Protease >> Tyrosinase

IC50: 40 µM (Tyrosinase)[1], Kd: 61.1 μM (Tyrosinase)[2].

Decapeptide-12 (P4, 0.01-10 mΜ) dose-dependently inhibits mushroom tyrosinase with an IC50 value of 40 µM, and inhibits human tyrosinase by 25-35% at 100 μM[1]. Decapeptide-12 (100 μM, 7 days) leads to 43% reduction in melanin content in melanocytes with no effect on cell proliferation[1]. Decapeptide-12 (peptide P4, 0-400 μM) inhibits the monophenolase reaction with an IC50 value of 123 μM[2]. Decapeptide-12 interact with tyrosinase with a Kd value of 61.1 μM[2]. Decapeptide-12 (100 μM, 72 h) increases transcription of SIRT1, SIRT3, SIRT6, and SIRT7 with reduced cytotoxicity in human neonatal keratinocyte progenitors[3]. Decapeptide-12 (0-1 mM, 72 h) reduces Phytohemagglutinin (PHA)-stimulated PBMC cells proliferation[3]. Cell Proliferation Assay[3] Cell Line: Phytohemagglutinin (PHA)-stimulated PBMC cells Concentration: 0, 0.025, 0.05, 0.1, 0.3, 1 mM Incubation Time: 72 h Result: Reduced cell proliferation by 28% at 0.05 mM and 54% at 0.1 mM. RT-PCR[3] Cell Line: Human neonatal keratinocyte progenitors Concentration: 3, 10, 30, 50, 100, 300, 500, 1000 μM Incubation Time: 72 h Result: Increased transcription of SIRT1 by 141% relative to untreated cells, increased SIRT3, SIRT6 and SIRT7 by 121%, 147% and 95%, respectively.

[1]. Anan Abu Ubeid, et al. Short-sequence oligopeptides with inhibitory activity against mushroom and human tyrosinase. J Invest Dermatol. 2009 Sep;129(9):2242-9.

[2]. Akihito Ochiai, et al. New tyrosinase inhibitory decapeptide: Molecular insights into the role of tyrosine residues. J Biosci Bioeng. 2016 Jun;121(6):607-613.

[3]. Basil M H, et al. Tyrosinase inhibitors with potent anti-senescence activity in human neonatal keratinocyte progenitors. J Dermatol Surg Res Ther, 2019, 2019: 30-39.